Korean J Urol.  2010 Feb;51(2):111-114.

Changes in Serum Prostate-Specific Antigen Levels after Potassium-Titanyl-Phosphate (KTP) Laser Vaporization of the Prostate

• Shim M
• Kwon T
• Kim SC
• Ha SH
• Ahn TY

Abstract

PURPOSE: The prostate-specific antigen (PSA) level decreases after transurethral resection of the prostate (TURP). However, changes in the PSA level after potassium-titanyl-phosphate (KTP) laser vaporization of the prostate are not well known. The aim of this study was to investigate the effect of KTP laser vaporization of the prostate on PSA levels in patients with benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS
Serum PSA levels were checked before and 1, 3, 6, and 12 months after the procedure in patients who underwent KTP laser vaporization between October 2004 and August 2008. Patients with prostate cancer, a history of urinary retention, or prostatitis during the follow-up period were excluded. The results for 278 patients were studied.
RESULTS
The mean age of the patients was 69.0+/-6.7 years (range, 50-91 years) and the mean preoperative PSA level was 2.72+/-2.93 ng/ml. The PSA level tended to be increased at 1 month after the operation (3.18+/-3.23 ng/ml, p=0.032) but decreased within 3 months and became stabilized after 6 months at 1.79+/-1.82 ng/ml (p<0.001).
CONCLUSIONS
PSA levels may increase after KTP laser vaporization for a certain period of time, but eventually decrease and become stabilized after 6 months. Therefore, it may be appropriate to wait up to 3 months if the PSA level rises after the procedure, and further investigation should be considered if the PSA level still remains high after 6 months.

Keyword

Prostate-specific antigen; Potassium titanyl-phosphate; Prostatic hyperplasia

MeSH Terms

Follow-Up Studies
Humans
Laser Therapy
Lasers, Solid-State
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Prostatic Neoplasms
Prostatitis
Urinary Retention
Volatilization
Prostate-Specific Antigen

Figure

• 

  FIG. 1 Patterns of change in the PSA level before and after KTP laser vaporization of the prostate. PSA: prostate-specific antigen, KTP: potassium-titanyl-phosphate.

Reference

1. Partin AW, Oesterling JE. The clinical usefulness of prostate-specific antigen: update 1994. J Urol. 1994; 152:1358–1368. PMID: 7523702.

2. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993; 42:276–282. PMID: 7691013.

3. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol. 1994; 25:281–287. PMID: 7519989.

4. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172:1297–1301. PMID: 15371827.

5. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992; 70(1 Suppl):291–301. PMID: 1376199.

6. Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol. 1996; 156:1035–1039. PMID: 8709302.

7. Choo SH, Han DH, Lee SW. The efficacy and safety of KTP photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: the 2-year results. Korean J Urol. 2008; 49:831–836.

8. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol. 2006; 20:580–585. PMID: 16903819.

9. Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol. 2005; 46:1251–1255.

10. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Prostate Patient Outcomes Research Team (PORT). Transurethral resection of the prostate among medicare beneficiaries in the United States: time trends and outcomes. Urology. 1994; 44:692–698. PMID: 7526526.

11. Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J. 2000; 113:299–302. PMID: 11775222.

12. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol. 2005; 174:1344–1348. PMID: 16145416.

13. Tasci AI, Tugcu V, Sahin S, Zorluoglu F. Rapid communication: photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective non-randomized bicenter trial with 2-year follow-up. J Endourol. 2008; 22:347–353. PMID: 18257671.

14. Ruszat R, Wyler SF, Seitz M, Lehmann K, Abe C, Bonkat G, et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int. 2008; 102:1432–1438. PMID: 18671785.

15. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology. 2008; 71:247–251. PMID: 18308094.

16. Schwartz I, Wein AJ, Malloy TR, Glick JH. Prostatic cancer after prostatectomy for benign disease. Cancer. 1986; 58:994–996. PMID: 2424590.

17. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein E, Diamandis EP, et al. The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol. 1996; 155:1658–1660. PMID: 8627847.

18. Cetinkaya M, Ulusoy E, Aki T, Kosan M, Kundak C, Aydos MM, et al. Effect of transurethral resection on serum free/total prostate-specific antigen levels in patients with benign prostatic hyperplasia. Urology. 1999; 53:118–120. PMID: 9886599.

19. Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S, Loray K, et al. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate. Eur Urol. 2005; 48:608–613. PMID: 16135396.

20. Aus G, Bergdahl S, Frösing R, Lodding P, Pileblad E, Hugosson J. Reference range of prostate-specific antigen after transurethral resection of the prostate. Urology. 1996; 47:529–531. PMID: 8638362.

21. Wolff JM, Boekels O, Borchers H, Jakse G, Rohde D. Altered prostate specific antigen reference range after transurethral resection of the prostate. Anticancer Res. 2000; 20:4977–4980. PMID: 11326651.